What’s Happening With AbbVie Stock

What's Happening With AbbVie Stock?

AbbVie stock (NYSE: ABBV) took a 5% hit yesterday, and the catalyst is clear: the U.S. FDA just approved Johnson & Johnson's Icotyde, the market's first oral IL-23 inhibitor. This is a significant threat because a daily pill offers a much more convenient alternative to AbbVie's injectable blockbuster, Skyrizi-the primary growth engine AbbVie has relied on to offset the Humira patent cliff. Earlier this month, Bristol Myers Squibb secured supplemental approval for Sotyktu in active psoriatic arthritis, making the immunology market even more crowded.

So, with the recent drop, is this the right time to buy AbbVie stock?

We don't think so. At its current price of around $210, AbbVie looks fairly priced. While the company has a strong operational foundation, its current valuation is simply too high to offer a compelling upside. Let's break down the numbers driving this conclusion.

How does AbbVie's valuation compare to the broader market?

It looks expensive. Whether you are paying for sales, free cash flow, or profit, ABBV trades at a clear premium compared to the S&P 500:

• Price-to-Sales (P/S): ABBV sits at 6.0, nearly double the S&P 500's 3.2.
• Price-to-Free Cash Flow (P/FCF): ABBV is at 20.7 versus the benchmark's 20.0.
• Price-to-Earnings (P/E): ABBV trades at a steep 87.2, vastly outpacing the S&P's 24.2.

What about top-line growth? Are revenues expanding fast enough to justify that premium?

Only marginally over the long term, though short-term momentum has picked up.

• Over the last three years, AbbVie's revenues have grown at a sluggish average rate of 1.9%, lagging behind the S&P 500's 5.7%.
• More recently, revenues grew 8.6% to $61 billion in the last twelve months, and the most recent quarter saw a good 10.0% jump to $17 billion.

Is the company generating strong profits from those revenues?

Operationally, yes, but the bottom line is mixed. AbbVie's profit margins are generally much higher than those of most companies in our coverage universe.

It boasts a considerable Operating Margin of 32.8% (generating $20 billion over the last four quarters) and an Operating Cash Flow Margin of 31.1%-both easily beating the S&P 500 averages.

For the last four-quarter period, AbbVie's Net Income was $4.2 Bil. While this translates to a lower GAAP Net Income Margin of 6.9% (vs. 12.8% for S&P 500), this figure is heavily weighed down by significant one-off acquired IPR&D and milestone expenses rather than underlying operational weakness.

Does AbbVie have a stable financial foundation to weather market changes?

Yes, the balance sheet is very strong. With $67 billion in debt against a massive $369 billion market cap, AbbVie maintains a highly desirable Debt-to-Equity Ratio of 18.3% (lower than the S&P 500's 21.8%). On the flip side, cash makes up only $5.3 billion of its $134 billion in total assets, yielding a relatively weak Cash-to-Assets Ratio of 3.9%.

How resilient is ABBV stock when the broader market falls?

It generally performs slightly better than the S&P 500 during major economic downturns.

• Inflation Shock (2022): ABBV declined by 23.3%, faring better than the S&P's 25.4% drop, and fully recovered its pre-crisis peak by February 2024.
• Covid Pandemic (2020): The stock fell 34.0%-virtually in line with the market's 33.9% drop-and bounced back rapidly by June 2020.

Riding out these market shocks requires patience, especially as immunology competition heats up. Portfolios win when stock picks fall short. Single stocks swing wildly, but staying invested matters. A well-built portfolio helps you stay invested, captures upside, and softens the blows from individual stocks. Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse group of 30 stocks that have collectively delivered stronger upside with reduced volatility compared to the broader indices. Discover the methodology behind these smoother, higher returns by checking the HQ Portfolio performance data.

Putting it all together: What's the final verdict on ABBV?

AbbVie boasts strong profitability and financial stability, alongside moderate growth and downturn resilience. Overall, the company is operationally strong, but this is already fully baked into its high valuation.

Because the stock is fairly priced, the risk-reward ratio simply doesn't favor the buyer at current levels. While the market may continue to pay a premium for AbbVie, buying now isn't the most strategic move, in our view. If you want to invest in ABBV, your best bet is to wait for a further dip. Alternatively, explore other pharmaceutical names with better current momentum, such as J&J, which has been faring very well lately and is actively disrupting AbbVie's market share.

Invest with Trefis Market-Beating Portfolios

See all Trefis Price Estimates